Early Stage Drug Development Company
We’re a high value-added company that applies photoisomerization conversion technology
Shareholders
Shareholders information
-
-
Shareholder No. Rate Remark Byong-Cheol Shin 1,613,326 72.66% CEO KNU Technology Holdings 367,794 16.56% - Minority Shareholders 239,364 10.78% - Total 2,220,484 100% As of December 31, 2021
Shareholder No. Rate Remark Byong-Cheol Shin 1,613,326 72.66% CEO KNU Technology Holdings 367,794 16.56% - Minority Shareholders 239,364 10.78% - Total 2,220,484 100% As of December 31, 2021